TGFB1 and colorectal carcinoma: To ascertain whether targeting the TGF-β/SMAD signaling pathway could prevent the migration of CRC cells, LY2157299 (also known as Galunisertib), a robust inhibitor of TGF-β receptor, was applied to further experiments.